Literature DB >> 8497072

Association of human immunodeficiency virus type 1 envelope glycoprotein with particles depends on interactions between the third variable and conserved regions of gp120.

R L Willey1, M A Martin.   

Abstract

Many regions within the envelope of human immunodeficiency virus type 1 (HIV-1) that affect its structure and function have been identified. We have previously reported that the interaction of the second conserved (C2) and third variable (V3) regions of gp120 influences the ability of HIV-1 to establish a productive infection in susceptible cells. To better understand the basis for this interaction, we have conducted structure-function analyses of envelope expressed from molecular proviral clones of HIV-1 containing defined mutations in C2 and V3 that individually and in combination differentially affect envelope function. The substitution of a glutamine for an asparagine residue (Q-267) at a potential asparagine-linked glycosylation site in C2, which severely impairs virus infectivity, reduces intracellular processing of gp160 into gp120, the association of gp120 with virions, and the ability of gp120 to bind to the HIV-1 cell surface receptor protein, CD4. The change of an arginine to an isoleucine codon in V3 (I-308), in the presence of the Q-267 mutation, restores virus infectivity to near wild-type levels by increasing the amount of gp120 associated with virions as compared with the Q-267 mutant but does not compensate for the Q-267-induced processing defect. The I-308 change in the context of the wild-type HIV-1 has no affect on processing, association, or CD4 binding. These results indicate that the impaired infectivity of the Q-267 mutant virus is due to a marked reduction in the amount of virion gp120 and suggest that the interaction of C2 and V3 stabilizes the association of gp120 with gp41.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497072      PMCID: PMC237716          DOI: 10.1128/JVI.67.6.3639-3643.1993

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport.

Authors:  R L Dewar; M B Vasudevachari; V Natarajan; N P Salzman
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

2.  Designing CD4 immunoadhesins for AIDS therapy.

Authors:  D J Capon; S M Chamow; J Mordenti; S A Marsters; T Gregory; H Mitsuya; R A Byrn; C Lucas; F M Wurm; J E Groopman
Journal:  Nature       Date:  1989-02-09       Impact factor: 49.962

3.  Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.

Authors:  A Pinter; W J Honnen; S A Tilley; C Bona; H Zaghouani; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

4.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Authors:  J S Allan; J E Coligan; F Barin; M F McLane; J G Sodroski; C A Rosen; W A Haseltine; T H Lee; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

5.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

6.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

Authors:  L A Lasky; G Nakamura; D H Smith; C Fennie; C Shimasaki; E Patzer; P Berman; T Gregory; D J Capon
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

7.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

8.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

9.  Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.

Authors:  J M McCune; L B Rabin; M B Feinberg; M Lieberman; J C Kosek; G R Reyes; I L Weissman
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

10.  In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.

Authors:  R L Willey; D H Smith; L A Lasky; T S Theodore; P L Earl; B Moss; D J Capon; M A Martin
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

View more
  22 in total

1.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.

Authors:  J P Moore; F E McCutchan; S W Poon; J Mascola; J Liu; Y Cao; D D Ho
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

3.  Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site.

Authors:  D G Fox; P Balfe; C P Palmer; J C May; C Arnold; J A McKeating
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants.

Authors:  A Carrillo; L Ratner
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

5.  Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid).

Authors:  H R Choe; J Sodroski
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1.

Authors:  L Stamatatos; A Werner; C Cheng-Mayer
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 7.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

8.  Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection.

Authors:  Liang Shang; Ling Yue; Eric Hunter
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

9.  Second-site long terminal repeat (LTR) revertants of replication-defective human immunodeficiency virus: effects of revertant TATA box motifs on virus infectivity, LTR-directed expression, in vitro RNA synthesis, and binding of basal transcription factors TFIID and TFIIA.

Authors:  F Kashanchi; R Shibata; E K Ross; J N Brady; M A Martin
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus.

Authors:  C C LaBranche; M M Sauter; B S Haggarty; P J Vance; J Romano; T K Hart; P J Bugelski; J A Hoxie
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.